Those receiving semaglutide not only lost around 10% of their body weight but also felt better and had nominally significant reductions in heart failure outcomes and total mortality, when compared to placebo-treated participants.
← all excerpts
The cardiology community begins to embrace obesity as an important target for cardiovascular health.
1
—
—